It is crucial to highlight that in T cell acute lymphoblastic leukemia (T-ALL), the Notch1 activating mutations typically occurs later in a sequence of genomic damages, suggesting that Notch1-based therapies may impede the efficacy targeted Notch1 therapy (De Bie et al., 2018). This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.